EP Patent

EP3870170B1 — Treatment of presbyopia and mydriasis with phentolamine

Assigned to Opus Genetics Inc · Expires 2026-02-25 · 0y expired

What this patent protects

Patent listed against phentolamine-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3870170B1
Jurisdiction
EP
Classification
Expires
2026-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Opus Genetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.